Contract Pharma Staff09.18.20
Catalent, Inc., a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, said the company is being added to the iconic S&P 500 index published by S&P Dow Jones Indices.
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data, and research, and home to many well-known financial market indicators, including the Dow Jones Industrial Average as well as the S&P 500.
“This designation is an affirmation of our strategy and the substantial progress we have made in executing it since our IPO in 2014,” said John Chiminski, chair and chief executive officer, Catalent. “None of this would have been possible without the passion and dedication of our 14,000 employees, whose commitment to our mission to help people live better, healthier lives has propelled Catalent to where we are today.”
As the supplier of over 70 billion doses of more than 7,000 products, for 1,000+ customers around the world, Catalent is pleased to help represent the healthcare sector in the S&P 500. Catalent now employs 14,000 people, including approximately 2,400 scientists, working on the latest medicines and consumer health products, including more than 50 COVID-19-related vaccine and treatment candidates.
The index change, which will see Catalent move from the S&P MidCap 400 to the S&P 500, will take place on Sept. 21, 2020.
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data, and research, and home to many well-known financial market indicators, including the Dow Jones Industrial Average as well as the S&P 500.
“This designation is an affirmation of our strategy and the substantial progress we have made in executing it since our IPO in 2014,” said John Chiminski, chair and chief executive officer, Catalent. “None of this would have been possible without the passion and dedication of our 14,000 employees, whose commitment to our mission to help people live better, healthier lives has propelled Catalent to where we are today.”
As the supplier of over 70 billion doses of more than 7,000 products, for 1,000+ customers around the world, Catalent is pleased to help represent the healthcare sector in the S&P 500. Catalent now employs 14,000 people, including approximately 2,400 scientists, working on the latest medicines and consumer health products, including more than 50 COVID-19-related vaccine and treatment candidates.
The index change, which will see Catalent move from the S&P MidCap 400 to the S&P 500, will take place on Sept. 21, 2020.